SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
A. M. Gonzalez-Angulo
No relevant relationships to disclose
W. E. Barlow
No relevant relationships to disclose
J. Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
F. Meric-Bernstam
No relevant relationships to disclose
D. F. Hayes
No relevant relationships to disclose
C. Moinpour
No relevant relationships to disclose
S. D. Ramsey
No relevant relationships to disclose
A. F. Schott
No relevant relationships to disclose
D. B. Sparks
No relevant relationships to disclose
K. S. Albain
Consultant or Advisory Role - Genomic Health
Honoraria - Genomic Health
G. N. Hortobagyi
No relevant relationships to disclose